NEW YORK (GenomeWeb News) – Emerald BioStructures and UCB have extended a collaboration aimed at identifying multiple targets in the drug discovery process, Emerald announced on Thursday.
The three-year extension provides the company with research funding, it said. The Bainbridge Island, Wash.-based firm also is eligible for milestone payments and royalties on future drug product revenues.
Additional financial and other details of the deal were not disclosed.
The collaboration between Emerald and UCB, a global biopharmaceutical firm based in Brussels, originally dates to 2009. Earlier this year, the firms said they had achieved a second milestone in their partnership and expanded the alliance.
Emerald is contributing its expertise in high-throughput crystallography and ligand characterization "to provide fragment screening and structural biology support for UCB's severe diseases discovery programs," it said.